Latissimus dorsi cardiomyoplasty was performed in 8 patients with dilated cardiomyopathy, normal coronary arteries and functional mitral regurgitation graded as mild or moderate. Patients were studied by equilibrium-gated angiography 1 week before operation and 4 months later. The functional mitral regurgitation was assessed by the ventricular amplitude ratio (VAR) derived from the Fourier amplitude image. One patient died of ventricular arrhythmia 5 months following operation. In the other 7 patients the clinical status improved from the New York Heart Association functional class III or IV to the functional class I or II. The left ventricular ejection fraction (EF) changed from 25 ± 7 to 26 ± 6%. The postoperative end-diastolic volume index was 78 ± 11 % of the preoperative value, and the VAR decreased from 2.01 ±0.54 to 1.49 ± 0.59 (p < 0.005). Our results suggest that in patients with severely depressed myocardial contractility the main short-term effect of dynamic cardiomyoplasty should be the reduction in the left ventricular diameters. Secondary to this effect, the functional mitral regurgitation would be reduced and the cardiac performance improved, although the global EF would not be modified.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.